Anemia and quality of life including anemia-related symptoms in patients with solid tumors in clinical practice

The aim of this study was to explore in a clinical setting the association between hemoglobin (Hb) level and quality of life (QoL) including anemia-related symptoms in patients with cancer disease. The study was performed in the outpatient units at the Oncology Clinic, Karolinska University Hospital, during spring 2004. One hundred-sixty patients responded to the questionnaires and Hb levels were available in 133 of their medical files. Anemia was not a common problem as only 12 out of 133 patients had an Hb level below 110 g/L. The Hb level was not related to general QoL but to FACT-An Trial Outcome Index (r, = 0. 186, p = 0.036), measuring anemia-felated symptoms as well as functional and physical well-being. However, two patients with Hb < 110 g/L had minor anemia-related symptoms (FACT AnS >= 40), while 22 patients with Hb >= 110 g/L had more pronounced symptoms (FACT AnS < 40). There was no difference in anemia-related symptoms between patients with and without ongoing cancer treatment, but patients with ongoing cancer treatment had decreased physical (p = 0.025) and functional (p = 0.011) well-being as compared to those without ongoing treatment. Patients with lung cancer on cancer treatment had lower FACT-An Trial Outcome Index than patients with breast cancer on treatment (mean values 71.8 and 99.1 for patients with lung and breast cancer, respectively, p = 0.009), and also a tendency to lower Hb levels (mean values 119 and 127 for patients with lung and breast cancer, respectively, p = 0.052). Physical and functional aspects might be more important to consider than increasing the Hb level to reduce the fatigue.